Novartis AG (ADR) (NVS)

NetscribePhrmtcl (96.34) Submitted: 12/15/06 9:13 AM : Start Price: $56.37 NVS Score: 15.84

Novartis is a Switzerland based pharmaceutical company manufacturing drugs for the treatments of nervous system, cardiovascular diseases and oncology. It has 138 projects in pipeline for pharmaceutical development focusing on areas of high unmet medi...

Report this Post Replies: 1 | Reply | Permalink

ABendall (31.63) Submitted: 10/20/06 1:22 PM : Start Price: $55.36 NVS Score: 13.61

Reasons to own Novartis:-
1) Hedge against a weaking US dollar
2) Years of patent protection remaining on major products
3) Fantastic product pipeline
4) Health care sector should be huge over the coming decade as baby-boom generation hit retirement ...

Report this Post Replies: 0 | Reply | Permalink

lvbobmvhp (88.10) Submitted: 9/29/06 5:00 PM : Start Price: $55.72 NVS Score: 12.55

typical Swiss secrecy besides a full pipeline of it's own and being a large player in generics they own a third of Roche (which owns 56% of Genentech)
and has a full pipeline of it's own +
$16 billion in cash for "acquisitions"

Report this Post Replies: 1 | Reply | Permalink

WoodvilleDale (86.29) Submitted: 8/24/06 11:41 PM : Start Price: $53.98 NVS Score: 12.93

This is the cream of the big pharmas with research labs right in nearby Cambridge. Conservative management, good record of acquisitions, strong drug portfolio... what's not to like. Well the shares are a little pricey but that should take care o...

Report this Post Replies: 1 | Reply | Permalink

weiwentg (83.75) Submitted: 10/11/06 2:09 PM : Start Price: $56.05 NVS Score: 12.09

Novartis is one of the best-run big pharma companies. It operates in branded and generic pharmaceuticals, with few patent expirations on the horizon. It's got a very defensible economic moat. It's undervalued.

Report this Post Replies: 1 | Reply | Permalink

interactdv (< 20) Submitted: 4/06/07 12:45 AM : Start Price: $53.95 NVS Score: -20.09

Zelnorm recall will result in a flurry of class action suits (as palgued Vioxx). While most will be deemed without merit there will be a flood of litigants eager to latch on to some of the extra cash that Novartis has at hand.
Long-term Novarti...

Report this Post Replies: 0 | Reply | Permalink

rwwine (78.63) Submitted: 9/28/06 1:01 PM : Start Price: $56.02 NVS Score: 12.15

Drug canadates inlcuding Telbivudine for the treatment of of hepatitis B virus looks very promising. Novartis will sell this drung into the European Union, Canada, Australia, Switzerland, Taiwan, South Korea and China after approval of telbivudine f...

Report this Post Replies: 0 | Reply | Permalink

Frogger21 (< 20) Submitted: 10/31/06 4:01 AM : Start Price: $57.95 NVS Score: 11.59

Strong new proprietary drug pipeline, but also able to capitalize on generic drug manufacturing, an increasingly important revenue stream.

Report this Post Replies: 0 | Reply | Permalink

latimerburned (80.74) Submitted: 10/20/06 10:34 AM : Start Price: $57.53 NVS Score: 11.39

Good combination of generic and patent drugs with a great pipeline and cash on the balance sheet.

Report this Post Replies: 0 | Reply | Permalink

daviddai (43.46) Submitted: 3/12/07 12:13 PM : Start Price: $54.71 NVS Score: 17.21

Leader in biotech innovation. Backed by its strong pipeline (the strongest among all other big pharmas), it has generated 11 billion in revenue in the last year. It has also hit jackpots after jackpots through acquisition of smaller firms that have...

Report this Post Replies: 0 | Reply | Permalink